Manjusha Gaglani - Concepedia

Author

Manjusha Gaglani

Also Known As

Alicia M Fry, For the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network, Gaglani, Manjusha, IVY Network, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network, Jefferey L. Burgess, M J Gaglani, M. Gaglani, M. J. Gaglani, MANJUSHA GAGLANI

317

Publications

16.7K

Citations

H-Index

Concepts

All Affiliations

Baylor Scott & White Health Centers for Disease Control and Prevention University of Michigan Vanderbilt University Medical Center University of Pittsburgh

About

Manjusha Gaglani is an author at Baylor Scott & White Health specializing in medicine, vaccination, and vaccine efficacy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	44	3.2K
2	Public Health	23	34	2.5K
3	Social Sciences	2	2	63
4	Health Sciences	1	1	19
5	Allergy	1	1	56

Manjusha Gaglani

166

Publications

16K

Citations

H-Index

Page 1

	Year	Citations
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway, MMWR Morbidity and Mortality Weekly Report	2021	787
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity Mark W. Tenforde, Wesley H. Self, Katherine Adams, JAMA	2021	671
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study Adam S. Lauring, Mark W. Tenforde, James D. Chappell, BMJ	2022	666
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway, New England Journal of Medicine	2021	519
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings Mark G. Thompson, Edward Stenehjem, Shaun J. Grannis, New England Journal of Medicine	2021	490
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, MMWR Morbidity and Mortality Weekly Report	2022	466
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 Wesley H. Self, Mark W. Tenforde, Jillian P. Rhoads, MMWR Morbidity and Mortality Weekly Report	2021	445
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 Mark G. Thompson, Karthik Natarajan, Stephanie A. Irving, MMWR Morbidity and Mortality Weekly Report	2022	427
Influenza Vaccine Effectiveness in the 2011–2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates Suzanne E. Ohmit, Mark G. Thompson, Joshua G. Petrie, Clinical Infectious Diseases	2013	341
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 Mark W. Tenforde, Samantha M. Olson, Wesley H. Self, MMWR Morbidity and Mortality Weekly Report	2021	319

Page 1